Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$7.14 +4.3%	$6.72	$5.73 ▼ $14.38	$586.84M	0.84	432,127 shs	172,470 shs
ENOV Enovis	$33.65 +0.6%	$32.99	$28.83 ▼ $49.83	$1.92B	1.7	889,392 shs	775,291 shs
LIVN LivaNova	$46.13 +0.1%	$43.64	$32.48 ▼ $57.35	$2.52B	0.9	638,670 shs	243,250 shs
NVCR NovoCure	$17.71 -1.0%	$17.70	$14.17 ▼ $34.13	$1.97B	0.72	1.13 million shs	534,101 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	0.00%	+5.52%	+9.40%	-14.24%	+21.29%
ENOV Enovis	0.00%	+5.89%	+5.65%	+3.47%	-24.25%
LIVN LivaNova	0.00%	+0.83%	+3.71%	+28.32%	-12.62%
NVCR NovoCure	0.00%	-1.64%	+5.89%	+7.37%	+4.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVS Bioventus	2.7285 of 5 stars	3.3	0.0	0.0	0.0	4.2	1.3
ENOV Enovis	3.548 of 5 stars	3.4	3.0	0.0	3.0	1.7	1.9
LIVN LivaNova	3.242 of 5 stars	3.5	3.0	0.0	2.6	1.7	1.3
NVCR NovoCure	3.687 of 5 stars	3.3	1.0	4.5	2.4	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVS Bioventus	2.67	Moderate Buy	$14.33	100.63% Upside
ENOV Enovis	2.80	Moderate Buy	$58.00	72.36% Upside
LIVN LivaNova	3.00	Buy	$59.29	28.52% Upside
NVCR NovoCure	2.67	Moderate Buy	$32.83	85.45% Upside

Current Analyst Ratings Breakdown

Latest BVS, NVCR, LIVN, and ENOV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	NVCR NovoCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$34.00
5/20/2025	LIVN LivaNova	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$60.00
5/14/2025	ENOV Enovis	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $70.00
5/13/2025	LIVN LivaNova	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00 ➝ $64.00
5/9/2025	ENOV Enovis	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$62.00 ➝ $55.00
5/9/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $57.00
5/8/2025	LIVN LivaNova	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $55.00
5/8/2025	LIVN LivaNova	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$55.00 ➝ $61.00
5/7/2025	BVS Bioventus	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$15.00
4/23/2025	NVCR NovoCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$42.00 ➝ $34.00
4/16/2025	NVCR NovoCure	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$29.00 ➝ $27.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVS Bioventus	$567.70M	1.03	$0.57 per share	12.58	$2.80 per share	2.55
ENOV Enovis	$2.11B	0.91	$19.23 per share	1.75	$45.10 per share	0.75
LIVN LivaNova	$1.25B	2.01	$4.24 per share	10.88	$24.31 per share	1.90
NVCR NovoCure	$605.22M	3.26	N/A	N/A	$3.33 per share	5.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVS Bioventus	-$156.23M	-$0.48	N/A	15.53	N/A	-7.11%	15.61%	4.01%	N/A
ENOV Enovis	-$825.49M	-$13.95	N/A	10.55	N/A	-37.65%	5.99%	3.44%	8/6/2025 (Estimated)
LIVN LivaNova	$63.23M	-$4.09	N/A	14.69	N/A	-17.41%	13.67%	6.68%	7/30/2025 (Estimated)
NVCR NovoCure	-$168.63M	-$1.51	N/A	N/A	N/A	-26.41%	-45.46%	-13.34%	7/24/2025 (Estimated)

Latest BVS, NVCR, LIVN, and ENOV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	LIVN LivaNova	$0.84	N/A	N/A	N/A	$332.20 million	N/A
7/24/2025	Q2 2025	NVCR NovoCure	-$0.40	N/A	N/A	N/A	$153.87 million	N/A
5/8/2025	Q1 2025	ENOV Enovis	$0.74	$0.81	+$0.07	-$0.98	$558.80 million	$558.83 million
4/24/2025	Q1 2025	NVCR NovoCure	-$0.47	-$0.31	+$0.16	-$0.31	$147.57 million	$154.99 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
ENOV Enovis	N/A	N/A	N/A	N/A	N/A
LIVN LivaNova	N/A	N/A	N/A	N/A	N/A
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVS Bioventus	1.85	1.41	0.99
ENOV Enovis	0.52	2.55	1.32
LIVN LivaNova	0.53	1.58	1.37
NVCR NovoCure	0.27	1.47	1.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVS Bioventus	62.94%
ENOV Enovis	98.45%
LIVN LivaNova	97.64%
NVCR NovoCure	84.61%

Insider Ownership

Company	Insider Ownership
BVS Bioventus	33.00%
ENOV Enovis	2.70%
LIVN LivaNova	0.29%
NVCR NovoCure	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVS Bioventus	1,200	82.14 million	54.46 million	Not Optionable
ENOV Enovis	7,367	57.12 million	55.58 million	Optionable
LIVN LivaNova	2,900	54.53 million	54.37 million	Optionable
NVCR NovoCure	1,488	111.49 million	105.33 million	Optionable

BVS, NVCR, LIVN, and ENOV Headlines

Recent News About These Companies

Summit Trail Advisors LLC Acquires 40,570 Shares of NovoCure Limited (NASDAQ:NVCR)

July 2 at 6:37 AM | marketbeat.com

Brokerages Set NovoCure Limited (NASDAQ:NVCR) PT at $32.83

July 2 at 3:07 AM | americanbankingnews.com

Strong week for NovoCure (NASDAQ:NVCR) shareholders doesn't alleviate pain of three-year loss

June 30, 2025 | finance.yahoo.com

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?

June 30, 2025 | zacks.com

NovoCure Limited (NASDAQ:NVCR) Shares Sold by Taylor Frigon Capital Management LLC

June 30, 2025 | marketbeat.com

Novocure to Report Second Quarter 2025 Financial Results

June 30, 2025 | businesswire.com

NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by Analysts

June 29, 2025 | marketbeat.com

Piper Sandler Reiterates Overweight Rating for NovoCure (NASDAQ:NVCR)

June 28, 2025 | americanbankingnews.com

Demystifying NovoCure: Insights From 4 Analyst Reviews

June 27, 2025 | benzinga.com

NovoCure's (NVCR) "Overweight" Rating Reiterated at Piper Sandler

June 27, 2025 | marketbeat.com

SG Americas Securities LLC Invests $527,000 in NovoCure Limited (NASDAQ:NVCR)

June 23, 2025 | marketbeat.com

NovoCure (NASDAQ:NVCR) Shares Down 3.4% - What's Next?

June 18, 2025 | marketbeat.com

What Makes NovoCure (NVCR) a New Buy Stock

June 18, 2025 | zacks.com

GAMMA Investing LLC Purchases 47,152 Shares of NovoCure Limited (NASDAQ:NVCR)

June 17, 2025 | marketbeat.com

Simon Quick Advisors LLC Takes Position in NovoCure Limited (NASDAQ:NVCR)

June 16, 2025 | marketbeat.com

NovoCure (NASDAQ:NVCR) Trading Up 6.5% - Here's Why

June 10, 2025 | marketbeat.com

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial

June 6, 2025 | zacks.com

What is Wedbush's Estimate for NovoCure FY2026 Earnings?

June 5, 2025 | marketbeat.com

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

June 2, 2025 | businesswire.com

Novocure data support pancreatic cancer approval, says Wells Fargo

June 2, 2025 | msn.com

Novocure study shows improved pancreatic cancer survival

June 2, 2025 | massdevice.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS, NVCR, LIVN, and ENOV Company Descriptions

Bioventus NYSE:BVS

$7.14 +0.29 (+4.29%)

As of 07/3/2025 03:02 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Enovis NYSE:ENOV

$33.65 +0.19 (+0.57%)

Closing price 07/3/2025 03:30 PM Eastern

Extended Trading

$33.66 +0.02 (+0.04%)

As of 07/3/2025 04:20 PM Eastern

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

LivaNova NASDAQ:LIVN

$46.13 +0.05 (+0.11%)

Closing price 07/3/2025 01:00 PM Eastern

Extended Trading

$46.10 -0.03 (-0.07%)

As of 07/3/2025 04:08 PM Eastern

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

NovoCure NASDAQ:NVCR

$17.70 -0.18 (-0.98%)

As of 07/3/2025 03:48 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time